Advanced searches left 3/3
Search only database of 8 mil and more summaries

Biotechnology in pharmaceutical manufacturing

Summarized by PlexPage
Last Updated: 02 July 2021

* If you want to update the article please login/register

General | Latest Info

The pharmaceutical and biotechnology industry produce drugs and other products that help people and animals live healthier lives, recover from injuries, and fight illnesses. From its humble origins in local pharmacies and apothecaries that prepared home remedies during the Middle Ages, pharmaceutical and biotechnology industry has grown into one of the leading industries in the world today. In United States, it is the third most profitable industry in terms of percentage of revenues, is home to cutting - edge biological and chemical research, and offers opportunities for people across a wide spectrum of careers, from scientists, physicians, and engineers to marketing and sales workers and human resources professionals. Pharma / Biotech companies produce three types of products: Prescription Therapeutics and prophylactics, diagnostics, and over - counter consumer products, such as drugs and vitamins. Some experts also place medical technology manufacturing under the umbrella of the Pharma / Biotech industry. In a general sense, pharmaceuticals are defined as medicinal drugs that are regulated by the US Food and Drug Administration or other regulatory bodies and are manufactured by pharmaceutical companies. Biotechnology, or Biotech, is the use of biological research techniques to develop products and processes derived from living organisms. Biotechnology techniques are applied at the molecular level and include DNA typing and cloning, genetic manipulation, and gene transfer of plants, animals, and microorganisms. Biotech products, sometimes called biologics, are products that are created using recombinant DNA Technology. According to FDA, biological products can be composed of sugars, proteins, or nucleic acids, or a combination of these substances. They may also be living entities, such as cells and tissues. In recent years, pharma and biotech sectors have become closely link. Since the mid 1980s, terms biopharmaceuticals and biopharma have referred to both types of products. In that time, many biopharmaceutical firms have emerge, which are owned by traditional pharmaceutical companies and large drug manufacturers. There are three main types of pharmaceutical companies. Large companies, sometimes know as innovative pharmaceutical companies, produce chemically - derive drugs and have many approved drugs on the market. They run huge research, development, and manufacturing efforts, sometimes with subsidiaries around the globe. Some innovative companies also produce biopharmaceuticals. Next are newer firms that often do have any approved drugs on the market, but that are involved in developing new drugs. Generic drug manufacturers, last type, produce drugs developed by other manufacturers after drug patent expires. Some generic companies also do original research and development to produce new drugs. Lines between Innovator and generic companies or between pharmaceutical and biotechnology companies have become increasingly blurred, and most major multinationals now incorporate both biologics and generics subsidiaries in their portfolios, according to 2016 Top Markets Report: Pharmaceuticals, from International trade Administration. As the prevalence of biosimilars grows, high manufacturing and regulatory costs involved in developing these drugs further cloud traditional distinctions between innovative and generic business models and investment cycles. Pharmaceutical companies are scattered throughout the United States, but the greatest concentrations exist in the Middle - Atlantic States and on the West Coast in California.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Human Insulin

With speed no longer seen in Drug Discovery and development, INSULIN was isolated FOR first time in 1921 from animal sources and commercialized within 12 months. Decades later, it took just four YEARS for developers to move from expressing RECOMBINANT INSULIN in bacteria to launching the world's FIRST biotechnology drug product. Scientists Frederick G. Banting and Charles H. Best, working in a lab provided by John J. R. Macleod at University of Toronto, isolated polypeptide hormone and began testing it in dogs. By 1922, with the help of James B. Collip and Pharmaceutical Company partners, researchers could purify and produce animal - base INSULIN in larger quantities. Insulin is produced by beta cells in the pancreas and is the most important hormone in the body to regulate blood glucose levels. A partial or complete lack of INSULIN causes diabetes, which, untreated, is often fatal in teenage years. The World Health Organization reports that an estimated 177 million people worldwide have diabetes. Although not a cure, INSULIN injections have been standard treatment since 1924. Before INSULIN was discover, diabetes was managed through diet, which allowed patients to survive, but generally FOR just a few YEARS after diagnosis. Remarkable medical results were achieved with FIRST INSULIN injections. Doctors finally had means to offer patients nearly normal quality of life, and it quickly became necessary to increase INSULIN production. Toronto scientists had trouble, however, with consistently isolating and purifying Drug. Connaught Laboratories in Canada, now part of Sanofi - Aventis, assist, and Eli Lilly & Co. Propose developing large - scale production methods. The university initially rebuffed offers from Lilly, but agreement was reached in May 1922. By that summer, Lilly was supplying quantities needed for clinical trials. To expand supply, universities give many royalty - free licenses. Among the licensees was Danish Nobel Laureate August Krogh, whose wife was diabetic. In December 1922, production started in Copenhagen, and the FIRST patient was treated there in March 1923. Krogh later founded Nordic INSULIN Laboratory, now part of Drug firm Novo Nordisk, with Danish physician Hans C. Hagedorn. Insulin was FIRST commercialized in Great Britain in May 1922, according to the University of Toronto, and by October 1923, it was BEING sold in the US and Canada. By 1924, large US and British companies were marketing INSULIN worldwide. It became a major product for Lilly and remains the foundation of Novo Nordisk's business. According to accounts from time, scientists ' fame rise rapidly. Macleod and Banting were awarded the 1923 Nobel Prize FOR Medicine or Physiology, which they share independently and respectively with Collip and Best. The Nobel Prize was FIRST FOR Canadian scientists, but the relationship between Banting and MacLeod was strained by differences about their contributions to Discovery. Since then, science, production, and delivery of INSULIN have been widely study. It was the FIRST protein FOR which chemical structure and molecular weight were determine.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Human blood clotting factors

Despite increasing interest in using plants as alternative expression hosts, studies on plant - made blood clotting factors reveal that plant - base systems are no alternative platform as long as current problems are not solve. Yields of recombinant plant - make blood clotting factors can be enhanced by modulating many factors such as promoter and terminator activities, codon optimization of transgene, matrix attachment regions, mRNA stability, translational efficiency, vector size, viral systems, and silencing suppressors. Production of bioactive vitamin K - dependent coagulation factors has not been achieved in plant - base systems yet. Vitamin K supplementation and expression of FIX, GGCX, PACE, and VKORC1, which have not been reported yet, can overcome current bottlenecks. Improvements in plant - make pharmaceuticals quality and quantity are as important as maximizing product yield. Optimization of downstream processes and associate costs have not been addrest in previous plant - make clotting Factor studies. To make plant - base systems competitive alternatives, upstream as well as downstream processes have to be performed in an advanced and cost - effective manner compared to traditional expression systems. Glycosylation can affect structure and function of protein and differences in plant and human glycosylation can induce immune responses in patients. Although principles of protein Asn - link glycosylation and N - glycan core structures are identical between plants and humans, there are differences in specific proximal and terminal sugar residues within glycan structures. Plant - specific 1 3 - fucose and 1 2 - xylose residues can be immunoreactive in humans,. Hence, it is desirable to produce proteins with humanized glycosylation. For this purpose, first step was to knock out plant - specific sugar residues by glyco - engineering. This was achieved for the first time by knocking out FucT and XylT genes in Arabidopsis thaliana and in Physcomitrella patens. Due to high homologous recombination rates in moss P. Patens, FucT and XylT genes have been knocked out and human - 1 4 - galactosyltransferase was stably introduced into the moss genome year later. With the advent of CRISPR / Cas9 technology, six genes responsible for xylose and fucose residues were knocked out in Nicotiana tabacum by - 2 suspension cells and in N. Benthamiana more recently. Moreover, overexpression of mammalian sialic acid biosynthesis pathway genes in N. Benthamiana enables in - vivo sialylation. Unlike N - glycosylation, which is partially conserved between all eukaryotes, plant O - glycosylation is fundamentally different from typical human mucin - type O - glycosylation. In mucins, O - glycans are incorporated via N - acetylgalactosamine into the hydroxyl side of serine or threonine residues in Golgi apparatus. Neither these O - glycans nor glycosyltransferases for human mucin - type O - glycosylation are present in plants. Although single Gal attachment to Ser residues on specific proteins is observed in plants, mainly arabinose chains and complex arabinogalactans are attached to 4 - trans - hydroxyproline, whereas no modification on Hyp is observed in mammals. Hence, elimination of non - human prolyl - hydroxylation, which might potentially be cause of immunogenic response in patients, can be a safe strategy to avoid adverse effects of plant - made pharmaceuticals. Addition of prolyl 4 - hydroxylase inhibitor 2 2 - dipyridyl to N. Tabacum Bright Yellow - 2 suspension cultures abolishes proline hydroxylation and arabinosylation.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

What is Biopharma?

If youre new to biotech, you might wonder what the difference is between the biotechnology industry and the pharmaceutical industry. Both industries produce medicine, so it is natural that they would become intertwine in most people's minds. Two get even further confuse when you consider the term Biopharma, which describes companies that use a combination of biotechnology and pharmaceuticals. Both the biotechnology and the pharmaceutical industries are known for researching and developing new drugs. Both industries have been around for hundreds of years, although modern biotechnology is much more recent. The two have some key differences, however. Here are the main differences between biotech and pharma: biotech companies, by definition, use processes of living organisms in their work. Biotech companies produce all kinds of products, but most focus on medicine and agriculture. Alcohol, plastic, washing detergents, and cosmetics are all produced using biotechnology. Some well - known biotechnology companies include Celgene Corp., Amgen Inc., Gilead Sciences, and Biogen Inc. Most biotech companies are on the smaller side. On the other hand, pharmaceutical industry uses artificial sources to create new medicines. They test their products through empirical screenings rather than genetic engineering. Major pharmaceutical companies include Johnson & Johnson, Novartis and Roche, and Bayer AG. Pharmaceutical companies are generally larger businesses. They are usually funded by shareholders and provide a lower risk business model. As you can see, these two industries differ not only in how they research and develop products, but also in their business models. Biotech companies generally rely on fundraising. As a result, entire process of coming up with new ideas for development, marketing, and sales of new products is completely different. It is necessary to sell your ideas before obtaining funding for any project. As a result, some well - merit biotechnology projects go unfunded. This is rare in the pharmaceutical industry. The term Biopharma refers to big pharmaceutical companies that utilize biotechnology. So while biotech and pharma are very different, they do overlap at times. If you were confused about the difference between biotechnology and pharmaceuticals, hopefully, you now have some clarity! Check my blog for more articles about biotechnology.


What is the Biopharmaceutical Industry?

Biopharmaceutical is the umbrella term for medical drugs that are created with biotechnology. Beer, wine, washing detergent, and everything plastic are all considered biotechnology product.S Humans have used biotech for millennia to breed animals and improve crops. In finance, biotech entails researching, developing, and producing mostly products for medical and agricultural purposes. Biopharmaceuticals are manufactured or extracted or semi - synthesize from biological sources, such as cells and living organisms. Traditional pharmaceuticals, on the other hand, are created instead through chemical synthesis. The biopharmaceutical industry also works on problems in Bio - defense, and has benefited from new breakthroughs in DNA Research. Biopharmaceuticals treat a wide - ranging list of ailments and include vaccines, blood components, allergenics, somatic cells, gene therapy, tissues, recombinant therapeutic proteins, and living cells. These proteins, antibodies, nucleic acids are leverage for therapeutic or in vivo diagnostic treatments. Theyre produced with the help of native biological source. Genentechs recommended human insulin as the first substance approved for therapeutic use. Eli Lily started marketing it in 1982. Among the most popular biopharma products include AbbVies Humira for arthritis, psoriasis, and Crohns disease, and more; Roches Rituxan to slow growth of tumors in several types of cancer; and Amgen / Pfizers Enbrel for autoimmune diseases.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

1. Increased regulatory demands.

Pharmaceutical and biopharmaceutical companies aim to create new medicines that cure diseases, alleviate symptoms and prolong life expectancy. Discovery, development and commercialisation of new medicines are long, risky and interdisciplinary processes that require teamwork among individuals with a wide range of scientific and business skills and knowledge. In 2007, estimate US 58. 8bn was spent by Pharmaceutical and Biotechnology companies on Pharmaceutical Research and Development activities, from early drug discovery to global regulatory approvals. 1 Pharmaceutical Research and Development processes can be divided into two basic stages - Drug discovery and Drug Development. These stages are demarcated by entry into clinical trials, with drug discovery occurring prior to initiation of clinical trials. Current analyses have estimated that an average of 10 - 15 years is required for discovery and development of successful new pharmaceutical product. 1 2 Pharmaceutical discovery and Development processes generally involve large and interdisciplinary project teams. In the earliest stages of drug discovery, research is generally biologically oriented and primarily laboratory base. Subsequently, chemistry expertise has become critical for pharmaceutical discovery, while biotechnology and bioengineering expertise has become important for discovery and validation of biological products, such as protein therapeutics or vaccines. For both the discovery of pharmaceutical and biological products, molecule characterisation requires laboratory testing of molecules for their pharmacological properties to predict their efficacy in humans. As clinical trials begin, expertise in biostatistics, Clinical trials design, bioethics and Regulatory Affairs are require. Throughout these multiyear efforts, legal experts protect discoveries with patents, market analysts assess changing marketplace of product offerings and clinical needs, and financial and business specialists raise funds to pay for research. Products themselves require scientific and technical knowledge to understand their use, so that even the salesforce must have a strong scientific background. Thus, many members of teams involved in all aspects of pharmaceutical discovery, development and commercialisation process possess scientific knowledge coupled with other business skills needed for their specific functions. The purpose of this study was to understand the functional composition of the current workforce in biotechnology and pharmaceutical companies. Most existing global pharmaceutical companies trace their origins to the chemical industry, and the need for new antibiotics that resulted from two world wars in the first half of the 20th century. Over the past 50 years, pharmaceutical industry has matured and consolidate, and is now dominated by very large, global companies with products in multiple therapeutic areas and annual revenues in billions of US. The origin of the biotechnology industry begins with academia's discovery of methods to manipulate DNA molecules, and the founding of companies based on applications of those technologies. Genentech was founded in 1976 and Amgen in 1980. 3 4 Both of these companies successfully use breakthroughs in molecular biology to produce new types of pharmaceutical product - expressed human proteins. In 1985, Genentech independently marketed its first product, Human recombinant growth hormone. This product brings company sales of 43. 6m in 1986. 5 Amgen, in 1989, marketed its first product, Epogen, that had sales of 140m by 1990.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

By: Isaiah Hankel, PhD

D in Anatomy & Cell Biology and an internationally recognized Fortune 500 consultant. He is an expert in the Biotechnology industry and specializes in helping people transition into cutting - edge career tracks. Isaiah believes that if you feel stuck somewhere in your life right now, you should make change. Dont sit still and wait for the world to tell you what to do. Start New project. Build your own business. Take action. Experimentation is the best teacher. Isaiah did his undergraduate work at Franklin & Marshall College in Pennsylvania and received his ph. D in Anatomy and Cell Biology from the University Of Iowa. Since graduating, he has been advancing his career in Cell Biology and business coaching. In the last two years, Isaiah has given over 250 seminars in 20 different countries throughout Europe, New Zealand, Australia and North America. Isaiah has worked with numerous leaders in the Biotechnology industry, including Lilly Pharmaceuticals, Leinco Technologies, Orflo Technologies, Bio - Rad Laboratories, Cellerant Therapeutics, Miltenyi Biotec, McCord Research, Expert Cytometry, Tree Star, Amgen, Celgene, Ambrx, BD Biosciences, Baxter Bioscience, Pfizer, Roche, and Genentech. He has also presented at Harvard University, Stanford University, Oxford University, Cambridge University, Cancer Research UK, University Of Amsterdam, German Cancer Research Center, Pasteur Institute, Curie Institute,. Jude Childrens Research Hospital, University Of Tasmania, University Of Sydney, University Of Western Australia, and many other prestigious institutions. Academia to business career transitions Entrepreneurship and startup Organization Corporate networking Product launch Social media and online marketing Confidence and charisma training Public speaking Time management accelerate learning Energy management finding your purpose in life is the first step to having a career of your dreams. Whether you want to work for a large corporation, start a nonprofit organization, or build a massively successful business of your own, it all starts with purpose. Nothing you do matters until you know where you are going. Find your focus and happiness and success will follow. - Isaiah Hankel, ph.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Sources

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

logo

Plex.page is an Online Knowledge, where all the summaries are written by a machine. We aim to collect all the knowledge the World Wide Web has to offer.

Partners:
Nvidia inception logo

© All rights reserved
2021 made by Algoritmi Vision Inc.

If you believe that any of the summaries on our website lead to misinformation, don't hesitate to contact us. We will immediately review it and remove the summaries if necessary.

If your domain is listed as one of the sources on any summary, you can consider participating in the "Online Knowledge" program, if you want to proceed, please follow these instructions to apply.
However, if you still want us to remove all links leading to your domain from Plex.page and never use your website as a source, please follow these instructions.